Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.31
+0.33 (4.73%)
Nov 22, 2024, 4:00 PM EST - Market closed
Lifecore Biomedical Revenue
Lifecore Biomedical had revenue of $24.71M in the quarter ending August 25, 2024, with 0.75% growth. This brings the company's revenue in the last twelve months to $128.44M, up 23.42% year-over-year. In the fiscal year ending May 26, 2024, Lifecore Biomedical had annual revenue of $128.26M with 24.20% growth.
Revenue (ttm)
$128.44M
Revenue Growth
+23.42%
P/S Ratio
1.74
Revenue / Employee
$245,122
Employees
524
Market Cap
269.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | Pro | Pro | Pro |
| May 27, 2018 | Pro | Pro | Pro |
| May 28, 2017 | Pro | Pro | Pro |
| May 29, 2016 | Pro | Pro | Pro |
| May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zynex | 193.67M |
| Poseida Therapeutics | 150.86M |
| Pulmonx | 79.30M |
| NeuroPace | 76.45M |
| Ocugen | 4.70M |
| Precigen | 3.96M |
| aTyr Pharma | 235.00K |
| Lyell Immunopharma | 63.00K |
LFCR News
- 1 day ago - Lifecore Biomedical Hosts Virtual Investor Day - GlobeNewsWire
- 10 days ago - Lifecore Biomedical to Present at Stephens Annual Investment Conference - GlobeNewsWire
- 15 days ago - Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024 - GlobeNewsWire
- 18 days ago - Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations - GlobeNewsWire
- 6 weeks ago - Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options - GlobeNewsWire
- 7 weeks ago - Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock - GlobeNewsWire